Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

670
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
670
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

602
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
602
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

514
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
514
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.7K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.1K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

French NOMADMUS Cohort Overview: Landscape Evolution of AQP4+NMOSD and MOGAD From 2010 to 2024.

Neurology·2026
Same author

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

External validation and improvement of an algorithm that identifies multiple sclerosis relapses in the French national healthcare claims database.

Multiple sclerosis and related disorders·2026
Same author

Kappa free light chain index or oligoclonal bands testing in clinical practice for multiple sclerosis diagnosis: An algorithm comparative study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

[Criteria for choosing treatment of multiple sclerosis].

La Revue du praticien·2026

Related Experiment Video

Updated: Aug 9, 2025

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

11.6K

[Neuromyelitis optica].

Thomas Roux1, Élisabeth Maillart1, Caroline Papeix1

  • 1Hôpital La Pitié- Salpêtrière, service de neurologie, Paris, France. CRC-SEP Paris. Centre des maladies inflammatoires rares du cerveau et de la moelle de l'enfant et de l'adulte (Mircem).

La Revue Du Praticien
|February 23, 2023
PubMed
Summary
This summary is machine-generated.

Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory central nervous system condition distinct from multiple sclerosis. Early treatment with corticosteroids and disease-modifying therapies is crucial for managing relapses and preventing further neurological damage.

More Related Videos

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

14.2K
Visual Evoked Potential Recording in a Rat Model of Experimental Optic Nerve Demyelination
06:49

Visual Evoked Potential Recording in a Rat Model of Experimental Optic Nerve Demyelination

Published on: July 29, 2015

12.4K

Related Experiment Videos

Last Updated: Aug 9, 2025

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

11.6K
Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

14.2K
Visual Evoked Potential Recording in a Rat Model of Experimental Optic Nerve Demyelination
06:49

Visual Evoked Potential Recording in a Rat Model of Experimental Optic Nerve Demyelination

Published on: July 29, 2015

12.4K

Area of Science:

  • Neurology
  • Immunology
  • Neuroinflammation

Context:

  • Neuromyelitis optica spectrum disorder (NMOSD) represents a group of central nervous system inflammatory conditions.
  • NMOSD is distinguished from multiple sclerosis by its specific clinical and immunological profiles.

Purpose:

  • To outline the characteristics, clinical manifestations, and management strategies for neuromyelitis optica spectrum disorder.
  • To emphasize the importance of early diagnosis and intervention in NMOSD.

Summary:

  • NMOSD is characterized by optic neuritis, transverse myelitis, and area postrema syndrome.
  • The presence of anti-aquaporin 4 antibodies is a key diagnostic marker for NMOSD.
  • The condition follows a relapsing course, necessitating prompt and aggressive treatment.

Impact:

  • Timely administration of high-dose intravenous corticosteroids and plasma exchange can be life-saving during acute relapses.
  • Initiation of disease-modifying treatment post-relapse is essential for preventing future attacks and long-term disability.
  • Understanding NMOSD's distinct pathophysiology aids in developing targeted therapeutic approaches.